Cell Therapy Materials & Upstream Processing/Analytics

CELL AND GENE THERAPY INSIGHTS

March 2023

Cell Therapy Materials & Upstream Processing/Analytics

Expert Insight

Challenges in obtaining cellular therapy starting material for patients with sickle cell disease

Challenges in obtaining cellular therapy starting material for patients with sickle cell disease

Yvette C Tanhehco

Commentary

Overcoming challenges to CAR-T cell therapies in India

Overcoming challenges to CAR-T cell therapies in India

A Uppal, R Chakrabarti, N Chirmule et al.

FastFacts

Increase quality & standardization of cellular starting material

Increase quality & standardization of cellular starting material

Viewpoint

Distributed manufacturing models for ATMPs: can they work: do we understand the pitfalls?

Distributed manufacturing models for ATMPs: can they work: do we understand the pitfalls?

Interview

Ensuring success in working with apheresis centers

Ensuring success in working with apheresis centers

Bridging the knowledge gap in donor cellular starting material quality & variability

Bridging the knowledge gap in donor cellular starting material quality & variability

22 February 2023

Webinars

Pain points to potential: Positioning process and analytical development for next-gen cell therapies

Pain points to potential: Positioning process and analytical development for next-gen cell therapies

Sarah Campion, Alex Sargent

Improve your speed to therapy and drive efficiency by integrating supply chain and manufacturing

Improve your speed to therapy and drive efficiency by integrating supply chain and manufacturing

Robert Lutskus, Matthew Lakelin

Scale-up and deliver allogeneic cell therapies to large patient populations

Scale-up and deliver allogeneic cell therapies to large patient populations

M Langtry, K Panchalingam, I Friedrich Ben-Nun

Overcoming challenges to succeed when transitioning into a cGMP environment

Overcoming challenges to succeed when transitioning into a cGMP environment

Kris Wronski

Cell therapy manufacturing and 21 CFR Part 11 compliance: Overview and considerations for instrument software

Cell therapy manufacturing and 21 CFR Part 11 compliance: Overview and considerations for instrument software

Ashley Smith, Brianna Volk

Navigating bottlenecks in cell therapy manufacturing: A versatile and scalable platform solution

Navigating bottlenecks in cell therapy manufacturing: A versatile and scalable platform solution

Peter Yates